Inactive Instrument

Antares Pharma, Inc.

ATRS

US0366421065

Medical Equipment, Supplies & Distribution

Raymond James Downgrades Antares Pharma to Market Perform From Strong Buy

Published on 04/14/2022 at 05:09 am EDT - Modified on 04/14/2022 at 05:10 am EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Antares Pharma, Inc.

22-05-24	Antares Pharma, Inc. Announces Management Changes	CI
22-05-24	Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from NASDAQ Composite Index	CI
22-05-24	Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P Pharmaceuticals Select Industry Index	CI
22-05-24	Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P Global BMI Index	CI
22-05-24	Antares Pharma, Inc.(NasdaqCM:ATRS) dropped from S&P TMI Index	CI
22-05-22	Halozyme Therapeutics, Inc. completed the acquisition of Antares Pharma, Inc..	CI
22-05-12	Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition	MT
22-05-10	Antares Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
22-04-26	Halozyme Therapeutics Launches Cash Tender Offer to Acquire Antares Pharma Shares	MT
22-04-14	Ladenburg Thalmann Downgrades Antares Pharma to Neutral From Buy	MT
22-04-14	HC Wainwright Downgrades Antares Pharma to Neutral From Buy; Price Target is $5.60	MT
22-04-14	Piper Sandler Downgrades Antares Pharma to Neutral From Overweight, Adjusts Price Target to $5.60 From $6	MT
22-04-14	Raymond James Downgrades Antares Pharma to Market Perform From Strong Buy	MT
22-04-13	Sector Update: Health Care Stocks Putting Up Modest Gains This Afternoon	MT
22-04-13	Health Care Up Amid Deal Activity -- Health Care Roundup	DJ

Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures, and commercializes, for itself or with partners, therapeutic products using its drug delivery systems. The Company products include XYOSTED (testosterone enanthate) injection, NOCDURNA (desmopressin acetate), OTREXUP (methotrexate) injection, Epinephrine Injection USP, Sumatriptan Injection USP, Makena Subcutaneous Auto Injector and Teriparatide Injection. Its testosterone enanthate injection product is indicated for testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Its desmopressin acetate is used for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per night to urinate.

Employees

202

Sector

Medical Equipment, Supplies & Distribution

More about the company